| INTRODUC TI ON
Influenza and respiratory syncytial virus (RSV) infections are responsible for substantial global morbidity and mortality annually, with the highest burden experienced by young children and older adults. [1] [2] [3] [4] [5] [6] [7] [8] In addition, a higher burden of influenza-and RSV-associated hospitalization has been reported among African children compared with children in other Regions. 2, 5, 8, 9 Nonetheless, studies were limited to a pediatric population and estimates from Africa were obtained from a very limited number of participating countries. Estimates of the national burden of influenza-and RSV-associated hospitalization across age groups are severely limited in many African countries, having been described only in five countries for influenza, 3,10-13 and two countries for RSV 4, 7, 10 on the continent.
The World Health Organization (WHO) has highlighted the need for influenza disease burden estimates especially from low-and middle-income countries. These estimates would enable governments to make informed evidence-based decisions when allocating scarce resources and planning intervention strategies to limit the impact and spread of the disease. 14 The effectiveness of RSV candidate vaccines is being evaluated, 15 and a better understanding of the burden of RSV-associated illness would assist in the formulation of polices should a vaccine become available.
We aimed to estimate the national and provincial number and rate of influenza-and RSV-associated severe acute respiratory ill- Ankadifotsy hospital). These hospitals were selected after a presurvey conducted to identify all health care facilities within the study district with the capacity of admitting patients with SARI. Six specialty hospitals such as eye or surgical hospitals were excluded from the pre-survey. Hospital admission books and medical records were reviewed to identify patients hospitalized with signs and symptoms consistent with the WHO SARI case definition reported below.
For each identified patient admitted at the selected hospitals, age, gender, dates of admission and discharge, and location of residence were recorded.
| DS-2: Influenza and RSV surveillance among patients hospitalized with SARI
We conducted active, prospective, hospital-based surveillance for SARI at the CENHOSOA from January 2011 through December 
| Estimation of the national number and rate of influenza-and RSV-associated SARI hospitalization
To estimate the national number and rate of influenza-and RSVassociated SARI hospitalization, we used a four-step approach. In
Step 1, we estimated the SARI hospitalization rate in Analamanga Region considered to be the base region in our estimation approach (where we conducted the retrospective record review and the prospective hospital-based surveillance for SARI). In Step 2, we estimated the SARI hospitalizations rates for the other regions using estimates from the base region. In Step 3, we estimated the influenza-and RSV-associated SARI hospitalizations rates using available virologic surveillance data for influenza and RSV. In Step 4, we obtained the number of influenza-and RSV-associated SARI hospitalizations using the estimated rates and the population at risk in each region. 13, 20, 21 The description of the estimation approach for each step is provided below and in Figure 1 . 
| Step 2: Estimation of SARI hospitalizations rates in the other regions
Estimates of SARI hospitalization rates for the other 21 regions in
Madagascar were derived by adjusting the Analamanga Region rate (base region-obtained in Step 1) for the regional-level prevalence of known risk factors for pneumonia obtained from the DHS (DS-3) as previously described (Step 2.a). 13, 20, 21 Risk factors included exposure to indoor air pollution, crowding, malnutrition, low birthweight, and non-exclusive breastfeeding. 13, 20, 21 The last three were only included for children aged <5 years. HIV infection prevalence, which was used as an adjustment factor in other similar studies, was excluded in our analysis because of the very low prevalence of HIV infection in Madagascar (<0.2% in the general population) 22 and the lack of region-specific prevalence estimates. The relative risk of SARI associated with each risk factor was determined from the published literature. 13, 20, 21, 23 In addition, we adjusted the regional rates by the proportion of ARI cases seeking care in the given region to the proportion of ARI cases seeking care in the base region using data from the DHS (DS-3) as previously described (Step 2.b). 13, 20, 21 The differential health care seeking behavior between regions among patients with ARI was used as a proxy for the differential health care seeking behavior among patients with SARI.
An adjustment factor >1 resulted in a greater SARI hospitalization rate in the given region relative to the base region and vice versa.
The equations used for the regional adjustments are provided in the Supporting Information.
| Step 3: Estimation of influenza-and RSVassociated SARI hospitalizations rates in all regions
We estimated the regional rates of influenza-and RSV-associated SARI hospitalization by multiplying the estimated regional SARI hospitalization rates (obtained in Steps 1 and 2) by the influenza and RSV positivity proportion obtained from influenza and RSV sentinel surveillance implemented among inpatients with SARI (DS-2). 13, 20, 21 The influenza and RSV positivity proportion was the number of positives cases divided by the total number of SARI cases tested.
| Step 4: Estimation of the number of influenza-and RSV-associated SARI hospitalizations in all regions
We estimated the regional number of influenza-and RSV-associated SARI hospitalizations by multiplying the regional influenza-and RSVassociated SARI hospitalization rates (obtained in Step 3) by the midyear population at risk in each region over the study period. 13, 20, 21 We obtained the 95% confidence intervals (CI) using bootstrap resampling over 1000 replications for all parameters included in the calculations. 13, 20, 21 This included (a) the age-and year-specific SARI hospitalization rates in the base region; (b) the regional prevalence of the risk factors for pneumonia; (c) the regional proportion of ARI cases seeking care; and (d) the age-specific influenza and RSV positivity proportion among SARI cases tested. The lower and upper limits of the 95% CI were the 2.5th and 97.5th percentiles of the estimated values obtained from the 1000 resampled datasets, respectively. Finally, we aggregated the regional estimates by the 6 provinces of Madagascar and nationally.
| Comparison of the demographic and clinical characteristics of influenza-and RSV-positive patients hospitalized with SARI
We compared the demographic and clinical characteristics of RSV-positive patients to those of influenza-positive patients hospitalized with SARI (DS-2) using unconditional logistic regression. For the multivariable model, we assessed all variables that were significant at P < 0.2 on univariate analysis and dropped non-significant factors (P ≥ 0.05) with manual backward elimination. Pairwise interactions were assessed by inclusion of product terms for all variables remaining in the final multivariable additive model. Patients in whom influenza virus and RSV were codetected were excluded from this analysis. In addition, for this analysis, we excluded fever and cough as these symptoms were surveillance inclusion criteria.
All statistical analyses were implemented using Stata 14.2 (StataCorp, College Station, TX, USA).
| Ethics
The influenza and RSV virologic data (DS-2) and the collection of SARI hospitalizations data (DS-1) are part of the disease surveil- 
| National number and rates of influenza-and RSV-associated SARI hospitalization
In individuals of all ages, the estimated mean annual number of influenza-associated SARI hospitalization was 6609 (95% CI: and ≥5 years, respectively ( Table 1 ). The estimated mean annual rate of RSV-associated SARI hospitalization was highest among children aged <5 years and lowest among individuals aged 25-44 years (rate:
1.3, 95% CI: 0.4-2.5 per 100 000 population).
A U-shaped trend of the magnitude of the mean annual influenza-and RSV-associated SARI hospitalizations rates was observed across age groups (Table 1) . Compared to RSV, mean annual influenza-associated SARI hospitalization rates were lower (with non-overlapping CIs) among children aged <5 years and higher among individuals aged ≥5 years. No substantial differences (with overlapping CIs) of the influenza-and RSV-associated SARI hospitalizations rates were observed between provinces (Table 1) ; however, variations were observed between years ( Table 2 ). The provincial mean annual number and rates of influenza-and RSV-associated SARI hospitalizations by age group are provided in Table S1 . The influenza-and RSV-associated SARI hospitalization rates by region are provided in Figure S1 . 
| Comparison of the demographic and clinical characteristics of influenza-and RSV-positive patients hospitalized with SARI

| D ISCUSS I ON
We reported national and provincial estimates of influenza-and RSV-associated SARI hospitalization in Madagascar over a 6-year period. Influenza-and RSV-associated SARI hospitalizations were substantial with those associated with RSV infection being the highest. Whereas SARI hospitalizations associated with both pathogens were observed across age groups, a differential burden among patients of different age was observed with children aged <5 years accounting for 67.6% and 96.0% of the total number of SARI hospitalizations associated with influenza virus and RSV infections, respectively. For both pathogens, the highest SARI hospitalization rates were observed among children aged <5 years and individuals aged ≥65 years, whereas individuals aged 25-44 years experienced the lowest rates.
Higher rates of influenza-associated respiratory hospitalizations among young children and the elderly have been reported in other case-based and ecological studies. 3, 24 The estimated rates of influenza-associated SARI hospitalization among Malagasy children aged <5 years (127.6 (108.4-145.7) per 100 000 population) were similar to those reported from studies conducted in South Africa (range: 153-186 per 100 000 population), 3 Kenya (270 per 100 000 population), 25 Ghana (135 per 100 000 population), 11 Rwanda (168 per 100 000 population), 12 and Zambia (187 per 100 000 population) 13 and global estimates for Africa (174 per 100 000 population), 5 and such estimates were higher compared to those of other Regions.
5
Among individuals aged ≥5 years, the Madagascar estimates (11.6 per 100 000 population) were generally consistent with the estimates obtained from similar studies conducted in Africa: South Africa (22.1 per 100 000 population), 3 Kenya (30.0 per 100 000 population), 25 Rwanda (11 per 100 000 population), 12 and Zambia (13 per 100 000 population). 13 Underlying medical conditions including HIV infection are known risk factors for influenza-associated severe illness. 3, [26] [27] [28] Differences in the prevalence of such conditions in these settings may explain some of the observed variation in the influenza-associated SARI hospitalization rates in this age group.
Cultural differences and differential access to health care across countries can also play a role in health care seeking behavior potentially also contributing to variability in hospitalization rates.
The estimated rates of RSV-associated SARI hospitalization among individuals aged <5 years (322.7 per 100 000 population) and ≥5 years (2.5 per 100 000 population) in Madagascar were lower than those reported in South Africa (1000 per 100 000 population among children aged <5 years vs 30 per 100 000 population among individuals aged ≥5 years). 4, 7 Kenya studies reported RSV-associated SARI hospitalization rates of 1360 and 11 per 100 000 population among patients aged <5 and ≥5 years, respectively. 10 In a global study of RSV-associated respiratory hospitalization among children aged <5 years, rates of 560 per 100 000 population were reported for low-income countries 8 ; however, in population-based studies conducted in low-to high-income countries across the world, the RSV-associated hospitalization rate among individuals aged >5 years ranged from 2.9 to 130 per 100 000 population. [29] [30] [31] [32] [33] [34] [35] SARI patients infected with RSV were more likely to be younger (<5 years of age) when compared to those infected with influenza virus. A higher hospitalization burden due to RSV compared with influenza virus among children aged <5 years has been described globally 2, 5, 8 as well as in other African settings. 3, 4, 7, 10 For both pathogens, the highest estimated hospitalization rates were observed in the Analamanga, Alaotra-Mangoro, Atsinanana, and Haute Matsiatra Region, and the lowest in the Melaky region.
Nonetheless, similar to South African, Kenyan, Rwandan, and Zambian studies, 12, 13, 20, 21 no difference (with overlapping CIs) in the provincial rates of influenza-associated SARI hospitalizations was observed, suggesting that geographical variations within countries may not affect substantially the burden associated with influenza virus or RSV infection. On the contrary, year-to-year variations were observed for both pathogens. This may be due to different circulating strains and patterns from year to year as well as a lower accuracy of annual estimates due to the small number of patients enrolled in a given year. This highlights the importance of estimating burden associated with influenza virus and RSV infection over several years.
Our study has limitations that warrant discussion. First, whereas
we attempted to account for potential geographical differences in rates by adjusting the base rate by the regional-level prevalence of known risk factors for pneumonia and health seeking behavior, such approach may not have accounted for the full spectrum of potential variability. Second, the completeness of the hospital records used for the retrospective record review could not be verified. An underestimation of the hospitalization rates could have occurred if not all admitted patients were recorded in the hospital books.
Third, we estimated the burden of influenza-and RSV-associated hospitalization only among patients hospitalized with SARI.
Influenza virus infection has been reported also among patients hospitalized for respiratory illness that do not meet the SARI case definition. Specifically in a study conducted in South Africa, 5.8%
of inpatients with respiratory illnesses that did not meet the SARI case definition tested positive for influenza. 36 In addition, ecological studies have suggested that influenza and RSV are responsible for hospitalizations and deaths also among patients presenting with circulatory illnesses or other non-respiratory and non-circulatory syndromes. 24, 26, 27 Lastly, individuals that may have developed influenza-or RSV-associated severe illness, but did not seek care, would have been missed in our study; hence, our estimates should be considered minimum estimates.
In conclusion, we reported a substantial hospitalization bur- vaccine is licensed for children aged <6 months, but this group may be protected through the vaccination of their mothers during pregnancy. 37, 38 The burden of RSV-associated SARI hospitalization was higher than those of influenza. Should a RSV vaccine become available it would have the potential to prevent a substantial number of severe illnesses, especially in children.
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